Skinvisible (SKVI) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 18.04% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 39.10% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 18.31% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 43.42% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 28.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.64% |
| Mar 31, 2026 | 74.86% |
| Dec 31, 2025 | 26.90% |
| Sep 30, 2025 | 26.33% |
| Jun 30, 2025 | -27.15% |
| Mar 31, 2025 | 8.15% |
| Dec 31, 2024 | -28.26% |
| Sep 30, 2024 | -31.08% |
| Jun 30, 2024 | -29.08% |
| Mar 31, 2024 | 7.76% |
| Dec 31, 2023 | -28.61% |
| Sep 30, 2023 | 38.66% |
| Jun 30, 2023 | -32.40% |
| Mar 31, 2023 | -48.32% |
| Dec 31, 2022 | 29.20% |
| Sep 30, 2022 | -85.99% |
| Jun 30, 2022 | 267.62% |
| Mar 31, 2022 | 3.78% |
| Dec 31, 2021 | 86.44% |
| Sep 30, 2021 | 46.68% |